Tumors As Organs: Biologically Augmenting Radiation Therapy by Inhibiting Transforming Growth Factor β Activity in Carcinomas

Overview

Journal Semin Radiat Oncol

Specialties Oncology
Radiology

Date 2013 Sep 10

PMID 24012338

Citations 17

Authors

Shisuo Du

Mary Helen Barcellos-Hoff

Affiliations

Soon will be listed here.

Abstract

Transforming growth factor β (TGFβ) plays critical roles in regulating a plethora of physiological processes in normal organs, including morphogenesis, embryonic development, stem cell differentiation, immune regulation, and wound healing. Though considered a tumor suppressor, TGFβ is a critical mediator of tumor microenvironment, in which it likewise mediates tumor and stromal cell phenotype, recruitment, inflammation, immune function, and angiogenesis. The fact that activation of TGFβ is an early and persistent event in irradiated tissues and that TGFβ signaling controls effective DNA damage response provides a new means to manipulate tumor response to radiation. Here we discuss preclinical studies unraveling TGFβ effects in cancer treatment and review TGFβ biology in lung cancer as an example of the opportunities for TGFβ pathway inhibition as a pharmaceutical approach to augment radiation therapy.

Citing Articles

Cancer Stem Cells in Tumor Modeling: Challenges and Future Directions.

Dogan E, Kisim A, Bati-Ayaz G, Kubicek G, Pesen-Okvur D, Miri A Adv Nanobiomed Res. 2021; 1(11).

PMID: 34927168 PMC: 8680587. DOI: 10.1002/anbr.202100017.

Regulation of aromatase in cancer.

Molehin D, Rasha F, Layeequr Rahman R, Pruitt K Mol Cell Biochem. 2021; 476(6):2449-2464.

PMID: 33599895 DOI: 10.1007/s11010-021-04099-0.

Research Strategies for Low-Survival Cancers.

Conway C, Collins D, McCann A, Dean K Cancers (Basel). 2021; 13(3).

PMID: 33573275 PMC: 7866553. DOI: 10.3390/cancers13030528.

Potential Molecular Targets in the Setting of Chemoradiation for Esophageal Malignancies.

Jabbour S, Williams T, Sayan M, Miller E, Ajani J, Chang A J Natl Cancer Inst. 2020; 113(6):665-679.

PMID: 33351071 PMC: 8600025. DOI: 10.1093/jnci/djaa195.

Positron Emission Tomography Imaging of Functional Transforming Growth Factor β (TGFβ) Activity and Benefit of TGFβ Inhibition in Irradiated Intracranial Tumors.

Gonzalez-Junca A, Reiners O, Borrero-Garcia L, Beckford-Vera D, Lazar A, Chou W Int J Radiat Oncol Biol Phys. 2020; 109(2):527-539.

PMID: 33007434 PMC: 7856163. DOI: 10.1016/j.ijrobp.2020.09.043.

References

Shimizu K, Nakata M, Hirami Y, Yukawa T, Maeda A, Tanemoto K . Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J Thorac Oncol. 2010; 5(5):585-90. DOI: 10.1097/JTO.0b013e3181d60fd7. View

Andreu P, Johansson M, Affara N, Pucci F, Tan T, Junankar S . FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell. 2010; 17(2):121-34. PMC: 3082507. DOI: 10.1016/j.ccr.2009.12.019. View

Joyce J, Pollard J . Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9(4):239-52. PMC: 3251309. DOI: 10.1038/nrc2618. View

Wiegman E, Blaese M, Loeffler H, Coppes R, Rodemann H . TGFbeta-1 dependent fast stimulation of ATM and p53 phosphorylation following exposure to ionizing radiation does not involve TGFbeta-receptor I signalling. Radiother Oncol. 2007; 83(3):289-95. DOI: 10.1016/j.radonc.2007.05.013. View

Annes J, Munger J, Rifkin D . Making sense of latent TGFbeta activation. J Cell Sci. 2002; 116(Pt 2):217-24. DOI: 10.1242/jcs.00229. View

Rifkin D . Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem. 2004; 280(9):7409-12. DOI: 10.1074/jbc.R400029200. View

Chen J, Yao P, Yuan A, Hong T, Shun C, Kuo M . Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res. 2003; 9(2):729-37. View

Jobling M, Mott J, Finnegan M, Jurukovski V, Erickson A, Walian P . Isoform-specific activation of latent transforming growth factor beta (LTGF-beta) by reactive oxygen species. Radiat Res. 2006; 166(6):839-48. DOI: 10.1667/RR0695.1. View

Song C, Tian X, Gelehrter T . Glucocorticoid receptor inhibits transforming growth factor-beta signaling by directly targeting the transcriptional activation function of Smad3. Proc Natl Acad Sci U S A. 1999; 96(21):11776-81. PMC: 18362. DOI: 10.1073/pnas.96.21.11776. View

10.

Formenti S, Demaria S . Systemic effects of local radiotherapy. Lancet Oncol. 2009; 10(7):718-26. PMC: 2782943. DOI: 10.1016/S1470-2045(09)70082-8. View

11.

Nakasone E, Askautrud H, Kees T, Park J, Plaks V, Ewald A . Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. Cancer Cell. 2012; 21(4):488-503. PMC: 3332002. DOI: 10.1016/j.ccr.2012.02.017. View

12.

Bristow R, Hill R . Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer. 2008; 8(3):180-92. DOI: 10.1038/nrc2344. View

13.

Zhang H, Chen X, Wang M, Wang J, Qi Q, Zhang R . Defective expression of transforming growth factor beta receptor type II is associated with CpG methylated promoter in primary non-small cell lung cancer. Clin Cancer Res. 2004; 10(7):2359-67. DOI: 10.1158/1078-0432.ccr-0959-3. View

14.

Abraham R . Checkpoint signaling: epigenetic events sound the DNA strand-breaks alarm to the ATM protein kinase. Bioessays. 2003; 25(7):627-30. DOI: 10.1002/bies.10310. View

15.

Ten Dijke P, Arthur H . Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol. 2007; 8(11):857-69. DOI: 10.1038/nrm2262. View

16.

Morty R, Konigshoff M, Eickelberg O . Transforming growth factor-beta signaling across ages: from distorted lung development to chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2009; 6(7):607-13. DOI: 10.1513/pats.200908-087RM. View

17.

Elenbaas B, Weinberg R . Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001; 264(1):169-84. DOI: 10.1006/excr.2000.5133. View

18.

Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N . CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med. 2005; 202(8):1075-85. PMC: 2213209. DOI: 10.1084/jem.20051511. View

19.

Ahn G, Brown J . Matrix metalloproteinase-9 is required for tumor vasculogenesis but not for angiogenesis: role of bone marrow-derived myelomonocytic cells. Cancer Cell. 2008; 13(3):193-205. PMC: 2967441. DOI: 10.1016/j.ccr.2007.11.032. View

20.

Ho C, Liao W, Wang C, Lu Y, Huang H, Chen H . TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 2007; 177(7):763-70. DOI: 10.1164/rccm.200704-641OC. View